Contact
Please use this form to send email to PR contact of this press release:
STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
TO:
Please use this form to send email to PR contact of this press release:
STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
TO: